Our Take
A political figure's crusade against psychiatric medication is not health policy; it is ideology dressed as public health, and it will harm people who depend on these drugs.
Why it matters
RFK Jr. holds significant influence over health policy conversations as a public figure with a large following. Medical messaging from non-clinicians that discourages evidence-based treatment can directly deter patients from seeking needed care.
Do this week
Healthcare providers: document patient discussions about antidepressant efficacy and risks in real time so treatment decisions rest on clinical evidence, not public pressure.
RFK Jr. Launches Antidepressant Reduction Campaign
Robert F. Kennedy Jr. is mounting a new public health initiative aimed at reducing antidepressant use in the United States. The effort, reported by the New York Times, represents an expansion of Kennedy's health advocacy portfolio beyond his earlier work on vaccine skepticism and environmental causes.
Kennedy's stated goal is to lower the number of Americans taking antidepressants. The campaign appears to frame psychiatric medication as a public health problem requiring systemic intervention, though specific policy proposals or clinical evidence supporting the reduction target have not been detailed in available reporting.
What the Evidence Actually Shows
Antidepressants remain among the most studied medications in medicine. Selective serotonin reuptake inhibitors (SSRIs) and other classes reduce symptoms of major depressive disorder and anxiety disorders in 60 to 70 percent of patients who take them (clinical trial data). They carry documented side effects and are not appropriate for every patient, but evidence-based psychiatry already accounts for this through individualized treatment planning.
The framing of antidepressant use as a systemic overtreatment problem lacks epidemiological support. The American Psychiatric Association and the World Health Organization both recognize depression as a serious condition requiring treatment, and access to antidepressants remains inadequate in many populations globally.
How Clinicians Should Respond
Psychiatrists, primary care doctors, and nurse practitioners should expect patients to raise concerns about antidepressant safety and efficacy based on social media and public figures' claims. The response is straightforward: anchor treatment decisions in the patient's symptoms, medical history, and shared decision-making.
Document the reasoning behind medication recommendations. If a patient asks whether they should stop an antidepressant because of public messaging, the conversation belongs in the clinic, not in the news cycle. Clinicians who have prescribed these drugs ethically have nothing to defend; they have evidence to present.